Kollins et al. A novel digital intervention for actively reducing severity of paediatric ADHD (STARS-ADHD): a randomised controlled trial. The Lancet. Digital health. 2020;2:e168-e178. PMID 33334505¶
One-paragraph summary¶
348 children randomized; TOVA API mean change 0.93 versus 0.03 after four weeks; no serious adverse events. (Kollins 2020, PMID 33334505).
Key findings¶
- 348 children randomized; TOVA API mean change 0.93 versus 0.03 after four weeks; no serious adverse events.
Limitations¶
- Objective attention change does not establish durable symptom, school or quality-of-life benefit.
Why it matters¶
It supported the first prescription digital-therapeutic pathway in pediatric ADHD.
Cited by wiki pages¶
- Psychosocial and digital treatment
- Clinical trials landscape
- Attention-deficit/hyperactivity disorder — overview